跳至主要内容
临床试验/NCT00068276
NCT00068276已完成2 期

Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial

Wake Forest University Health Sciences2 个研究点 分布在 1 个国家开始时间: 2003年7月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
试验地点
2

研究概览

简要总结

RATIONALE: Cholecalciferol (vitamin D) may improve quality of life by increasing blood counts, decreasing fatigue, and improving other symptoms of myelodysplastic syndrome.

PURPOSE: This phase II trial is studying how well cholecalciferol works in treating patients with myelodysplastic syndrome.

详细描述

OBJECTIVES:

  • Determine the efficacy of cholecalciferol, in terms of hematological improvement, in patients with low- or intermediate-risk myelodysplastic syndromes.
  • Determine the effect of this drug on disease symptoms, fatigue, and the overall health-related quality of life of these patients.

OUTLINE: This is an open-label, pilot study.

Patients receive oral cholecalciferol once daily. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 120 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验